会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 74. 发明授权
    • Immunoassay method and immunoassay reagent kit to be used therein
    • 免疫测定法和免疫测定试剂盒用于其中
    • US07056682B2
    • 2006-06-06
    • US10474755
    • 2002-12-27
    • Akihito KameiNoriko KenjoTatsuro KawamuraMahito Hirai
    • Akihito KameiNoriko KenjoTatsuro KawamuraMahito Hirai
    • G01N33/53
    • G01N33/5375G01N33/536G01N33/539G01N33/542
    • In step St1 shown in FIG. 1, a reaction system including a sample for which the content of a subject substance is to be measured, a specific-binding substance specifically binding to the subject substance, and phthalic acid or phthalate salt is constructed. The pH of the reaction system is set at less than 7. When the subject substance is an antigen, the specific-binding substance is an antibody. In reverse, when the subject substance is an antibody, the specific-binding substance is an antigen. In step St2 in FIG. 1, an optical property of the reaction system is measured. When agglutinate complexes are produced in the step St1, the reaction system becomes turbid, causing a change in scattered light intensity, transmitted light amount and the like. Therefore, by measuring the scattered light intensity, the transmitted light amount or the like, the degree of turbidity of the reaction system can be estimated.
    • 在图1所示的步骤St 1中, 如图1所示,构成了包含被测定物质含量的样品,特异性结合物质的特异性结合物和邻苯二甲酸或邻苯二甲酸盐的反应体系。 反应体系的pH设定为小于7.当目标物质为抗原时,特异性结合物质为抗体。 相反,当目标物质是抗体时,特异性结合物质是抗原。 在图3的步骤St2中 如图1所示,测定反应体系的光学特性。 当在步骤St 1中产生凝集络合物时,反应体系变得混浊,导致散射光强度,透射光量等的变化。 因此,通过测量散射光强度,透射光量等,可以估计反应体系的浊度。
    • 75. 发明申请
    • Process and apparatus for separating and recovering particles from a liquid sample
    • 用于从液体样品中分离和回收颗粒的方法和设备
    • US20050048474A1
    • 2005-03-03
    • US10920992
    • 2004-08-18
    • James Amburgey
    • James Amburgey
    • C12M1/12C12Q1/04C12Q1/24C12Q1/70G01N33/537G01N33/539
    • G01N33/5375C12M47/02C12Q1/24G01N33/539
    • The process and apparatus of this invention can be used to separate and recover particles from a liquid sample. The preferred embodiment of this invention is to separate and recover microorganisms, particularly Cryptosporidium oocysts, from a variety of environmental sources. The process consists of applying a municipal drinking water coagulation scheme to an environmental water sample, and the aforementioned water sample is then filtered through an apparatus containing a granular filter material. The analyte is then recovered by agitating the filter vigorously (with a dispersing agent inside) and removing the eluent from the filtration apparatus. The eluent can then by aliquotted and assayed by any means available. The floc resulting from the coagulant addition can typically be dissolved at low pH. The filter apparatus is simply a container that allows the passage of water through a granular material while retaining the granular material via a mesh, screen, or similar material.
    • 本发明的方法和装置可用于从液体样品中分离和回收颗粒。 本发明的优选实施方案是从各种环境来源分离和回收微生物,特别是隐孢子虫卵囊。 该方法包括将市政饮用水凝结方案应用于环境水样品,然后通过含有粒状过滤材料的装置过滤上述水样品。 然后通过剧烈搅拌过滤器(使用分散剂)并从过滤装置中除去洗脱液来回收分析物。 然后可以通过任何可用的方法将洗脱液等分和测定。 凝结剂添加产生的絮凝物通常可以在低pH下溶解。 过滤装置简单地是允许水通过颗粒材料的容器,同时通过网状物,筛网或类似材料保持颗粒材料。
    • 76. 发明授权
    • Assay of blood or other biologic samples for target analytes
    • 测定目标分析物的血液或其他生物样品
    • US5635362A
    • 1997-06-03
    • US247336
    • 1994-05-23
    • Robert A. LevineStephen C. WardlawRodolfo R. RodriguezAdrien P. MalickAlvydas J. Ozinskas
    • Robert A. LevineStephen C. WardlawRodolfo R. RodriguezAdrien P. MalickAlvydas J. Ozinskas
    • G01N33/543B01L3/14G01N33/49G01N33/537G01N33/569G01N33/58G01N33/558
    • B01L3/5021G01N33/491G01N33/5375G01N33/56972G01N33/585Y10S435/81Y10S435/967Y10S435/971Y10S435/973Y10S436/805Y10S436/81Y10S436/824Y10S436/829Y10T436/111666
    • A patient's health may be diagnosed by centrifuging blood samples in a transparent tube, which tube contains one or more bodies or groups of bodies such as floats, inserts, liposomes, or plastic beads of different densities. Each density-defined body carries analyte-capture binding materials such as antigens or antibodies, which are specific to an epitope, or other specific high affinity binding site on a target analyte which target analyte may be in the blood or other sample being tested; and the level of which analyte is indicative of the patient's health. At least one labeled binding material which is also specific to an epitope, or other specific high affinity binding site on the target analyte is added to the sample so as to form labeled binding material/analyte/body complexes in the sample. Upon centrifugation, the complexes will settle out in different areas in the tube according to the respective density of the body or bodies; and the degree of label emission of the complex layers can enable qualitative and/or quantitative analyses of the sample to be made. Unbound labeled binding materials will be separated from the complexed layers by the washing action of ascending or descending components of the sample during the centrifugation step. Unbound labeled binding material will thus not interfere with the analysis.
    • 可以通过将透明管中的血液样品离心来诊断患者的健康,该管包含一个或多个不同密度的浮体,插入物,脂质体或塑料珠的主体或组。 每个密度定义的身体携带分析物 - 捕获结合材料,例如抗原或抗体,其对靶分析物是特异性的,或靶分析物上的其它特异性高亲和力结合位点,其目标分析物可能在待测试的血液或其他样品中; 并且其分析物的水平表示患者的健康。 将至少一种对靶分析物上的表位或其他特异性高亲和力结合位点特异性的标记结合物质加入到样品中,以便在样品中形成标记的结合材料/分析物/身体复合物。 离心后,复合物将根据身体或身体的相应密度沉淀在管中的不同区域; 并且复合层的标签发射程度可以使得要进行样品的定性和/或定量分析。 通过在离心步骤期间样品的上升或下降组分的洗涤作用,未结合的标记结合材料将从复合层分离。 因此,未结合的标签结合材料不会影响分析。